Summary
George Kailas, founder of retail investor platform Prospero.ai, has launched Aethon Fund with $50 million in capital. The hedge fund draws on a research base built over two decades and signal tools developed through Prospero.ai, which has more than 20,000 monthly active users. The raise includes an anchor allocation from a fund of funds alongside commitments from other ultra-high-net-worth and institutional investors.
Aethon's research stack includes nine daily signals across more than 2,000 stocks, a social sentiment system tracking Reddit, X, and StockTwits, an analyst-rating model weighting price targets by forecasting accuracy, and a model predicting return probabilities across stocks and ETFs. The fund runs multiple strategies in parallel — long, short, mean-reversion, momentum, and stealth accumulation — with AI handling execution while the investment team focuses on signal research.
Key Facts
- Fund: Aethon Fund; $50M in capital
- Founder: George Kailas (also founded Prospero.ai in 2019)
- Prospero.ai: 20,000+ monthly active users; 200,000+ retail investors in live calls
- Signals: 9 daily signals across 2,000+ stocks
- Social sentiment: Reddit, X, StockTwits tracking
- Analyst model: weights price targets by recent forecasting accuracy
- Strategies: long, short, mean-reversion, momentum, stealth accumulation
- Execution: AI handles execution; team focuses on signal research
- Risk management: preset profit targets, stop-loss, trailing, time stops
- Variance risk premium: adjusts long/short exposure by market regime
- Leadership: Dave Lauer (ex-Citadel) as CTO; Ezi Ozoani (ex-Hugging Face) as Head of AI
- Kailas becomes Chairman of Prospero.ai; Adam Plante becomes CEO
- A percentage of Aethon's proceeds directed back to Prospero.ai
Why It Matters
Aethon represents a new model of hedge fund that blurs the line between retail and institutional investing. By building signals through real-world feedback from 200,000+ retail investors on Prospero.ai, Kailas claims to have developed a signal library tested in live conditions rather than just backtests. The fund's unusual commitment to transparency — planning to disclose how signals work on specific stocks — could challenge industry norms around proprietary research secrecy.